N
152.65
0.69 (0.45%)
| Penutupan Terdahulu | 151.96 |
| Buka | 152.00 |
| Jumlah Dagangan | 192,434 |
| Purata Dagangan (3B) | 954,719 |
| Modal Pasaran | 15,219,576,832 |
| Harga / Pendapatan (P/E TTM) | 36.43 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.28 |
| Harga / Jualan (P/S) | 5.80 |
| Harga / Buku (P/B) | 5.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | 12.68% |
| Margin Operasi (TTM) | 4.14% |
| EPS Cair (TTM) | 2.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -81.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.45% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | 529.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 235.48 M |
| Pulangan Atas Aset (ROA TTM) | 8.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Neurocrine Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.7
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.70 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 98.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 30 Sep 2025 | 1,763,105 |
| Los Angeles Capital Management Llc | 30 Sep 2025 | 1,202,756 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 203.00 (Citigroup, 32.99%) | Beli |
| Median | 179.00 (17.27%) | |
| Rendah | 160.00 (RBC Capital, 4.82%) | Beli |
| Purata | 179.20 (17.40%) | |
| Jumlah | 10 Beli | |
| Harga Purata @ Panggilan | 139.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 11 Nov 2025 | 173.00 (13.33%) | Beli | 147.29 |
| 20 Oct 2025 | 168.00 (10.06%) | Beli | 141.33 | |
| JP Morgan | 03 Nov 2025 | 179.00 (17.27%) | Beli | 141.96 |
| Truist Securities | 30 Oct 2025 | 172.00 (12.68%) | Beli | 138.04 |
| Canaccord Genuity | 29 Oct 2025 | 164.00 (7.44%) | Beli | 138.02 |
| Citigroup | 29 Oct 2025 | 203.00 (32.99%) | Beli | 138.02 |
| 21 Oct 2025 | 175.00 (14.65%) | Beli | 142.65 | |
| Needham | 29 Oct 2025 | 184.00 (20.54%) | Beli | 138.02 |
| 22 Sep 2025 | 170.00 (11.37%) | Beli | 146.62 | |
| Piper Sandler | 29 Oct 2025 | 179.00 (17.27%) | Beli | 138.02 |
| RBC Capital | 29 Oct 2025 | 160.00 (4.82%) | Beli | 138.02 |
| 05 Sep 2025 | 149.00 (-2.39%) | Beli | 144.10 | |
| Stifel | 29 Oct 2025 | 183.00 (19.89%) | Beli | 138.02 |
| UBS | 09 Oct 2025 | 195.00 (27.75%) | Beli | 138.47 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MORROW GEORGE J | - | 143.53 | -15,000 | -2,152,950 |
| Jumlah Keseluruhan Kuantiti Bersih | -15,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,152,950 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 143.53 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MORROW GEORGE J | Pengarah | 25 Nov 2025 | Jual automatik (-) | 15,000 | 143.53 | 2,152,950 |
| MORROW GEORGE J | Pengarah | 25 Nov 2025 | Pelaksanaan pilihan | 15,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |